A Series C funding round has brought in $60 million for Dicerna Pharmaceuticals, a Watertown, Mass.-based firm developing novel treatments using its Dicer enzyme and technologies. The firm plans to use the money to take two programs into clinical development and to further develop preclinical candidates. "Over the next two years we will launch several Dicer Substrate pharmaceuticals into clinical development, targeting well-understood orphan diseases as well as classic undruggable targets in oncology," Dicerna CEO Douglas Fambrough said.

Related Summaries